| Identification | Back Directory | [Name]
GI 181771 | [CAS]
305366-98-7 | [Synonyms]
GI 181771
GI181771X
CABBMMXFOOZVMS-PMERELPUSA-N
Benzoic acid, 3-[[[[(3S)-2,3,4,5-tetrahydro-1-[2-[(1-methylethyl)phenylamino]-2-oxoethyl]-2,4-dioxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]amino]carbonyl]amino]- | [Molecular Formula]
C34H31N5O6 | [MDL Number]
MFCD18782592 | [MOL File]
305366-98-7.mol | [Molecular Weight]
605.65 |
| Chemical Properties | Back Directory | [Boiling point ]
894.3±65.0 °C(Predicted) | [density ]
1.41±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [pka]
4.16±0.10(Predicted) |
| Hazard Information | Back Directory | [Uses]
GI 181771 is a cholecystokinin 1 receptor agonist investigated for the treatment of obesity. | [References]
[1] Myer JR, et al. Species- and dose-specific pancreatic responses and progression in single- and repeat-dose studies with GI181771X: a novel cholecystokinin 1 receptor agonist in mice, rats, and monkeys. Toxicol Pathol. 2014 Jan;42(1):260-74. DOI:10.1177/0192623313506792
[2] Roses AD, et al. Stimulation of cholecystokinin-A receptors with Gl181771X: a failed clinical trial that did not test the pharmacogenetic hypothesis for reduction of food intake. Clin Pharmacol Ther. 2009 Apr;85(4):362-5. DOI:10.1038/clpt.2008.192 |
|
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 13348960310; |
| Website: |
https://www.weikeqi-biotech.com/ |
|